Dr. Lior Shaltiel reports

NUREXONE'S STRATEGIC UPDATE: SUBMISSION OF OTCQB LISTING APPLICATION TO INITIATE US FINANCIAL PRESENCE

Nurexone Biologic Inc. intends to broaden its market reach through a recently filed application for listing on the OTCQB Venture Market in the United States. Listing on the OTCQB is subject to approval of the OTC Markets Group Inc.

The OTCQB, a reputable U.S. trading platform operated by OTC Markets Group, serves as a pivotal gateway for both domestic and international companies aiming to bolster their visibility and accessibility to American investors. By maintaining stringent standards for transparency and compliance, the OTCQB fosters an environment conducive to informed trading, thus enhancing opportunities for companies to attract investment and optimize shareholder value.

The company is delighted to announce that it has also applied for DTC eligibility by the Depository Trust Company for its shares on the OTCQB Venture Market. Approval for DTC eligibility will expand the company's stock reach to a wider audience of potential investors and brokerage firms that mandate additional compliance measures. This move aims to enhance accessibility and potentially boost liquidity through on-line transactions.

Yoram Drucker, chairman of Nurexone's board, commented: "Expanding our presence to the OTCQB underscores our commitment to enhancing investor engagement and liquidity for our shareholders. OTCQB listing will offer U.S. investors an easy way to invest in Nurexone. As pioneers in the development of exosome-loaded nanodrugs for a wide range of clinical indications, we are pleased to offer broader opportunities for the investing public to join us on this innovative journey."

Nurexone's common shares will continue trading on the TSX Venture Exchange and on several stock exchanges in Germany, including Frankfurt, Munich or Tradegate. If, and when, the company's common shares start to trade on the OTCQB, the company's common shares will continue to trade on the TSX-V under the symbol NRX. The company remains dedicated to keeping shareholders informed throughout the application process.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered central nervous system injuries. The company's first product, ExoPTEN for acute spinal cord injury, was proved to recover motor function in 75 per cent of laboratory rats when administered intranasally. ExoPTEN has been granted orphan drug designation by the Food and Drug Administration. The Nurexone platform technology is expected to offer novel solutions to drug companies interested in non-invasive targeted drug delivery for other indications.

We seek Safe Harbor.